INTRODUCTION

• Symptomatic, not interfering with ADL

METHODS

Severity

Poster 561

Figure 1. Computed tomography scans showing presentation and resolution of noninfectious pneumonitis.

Figure 2. Cumulative risk estimates for initial onset of noninfectious pneumonitis.

Table 3. Incidence and Grade of Preferred AE Terms Included in Noninfectious Pneumonitis in Patients Receiving EVE+EXE

RISK ASSESSMENT

• Risk assessment should be completed before initiating mTOR inhibitor therapy (Table 2). Explain surveillance timeframe to patients to improve acceptance and adherence

CONCLUSIONS

• Noninfectious pneumonitis and related pulmonary events are reversible

REFERENCES